No full-text available
To read the full-text of this research,
you can request a copy directly from the authors.
Consenso para la mejora de la atención integral de los pacientes con insuficiencia cardíaca aguda
Abstract
Resumen
El último consenso sobre insuficiencia cardíaca aguda de la Sociedad Española de Cardiología, la Sociedad Española de Medicina Interna y la Sociedad Española de Medicina de Urgencias y Emergencias se elaboró en 2015, por lo que era necesaria una actualización para revisar las diversas novedades relacionadas con la temática de insuficiencia cardíaca aguda que han ido apareciendo los últimos años. Entre ellas están la publicación de las nuevas guías europeas sobre insuficiencia cardíaca en el 2016, nuevos estudios sobre el manejo farmacológico de los pacientes durante la hospitalización y novedades sobre diversos aspectos relacionados con la insuficiencia cardíaca aguda, tales como el abordaje precoz, terapia intermitente, insuficiencia cardíaca avanzada y congestión refractaria. Por ello, este consenso se elaboró con la intención de actualizar todos los aspectos relacionados con la insuficiencia cardíaca aguda y proporcionar un documento que detallase de manera completa el diagnóstico, tratamiento y manejo de esta enfermedad.
Objectives
This work aims to analyze if hospitalization in short-stay units (SSU) of patients diagnosed in the emergency department with acute heart failure (AHF) is effective in terms of the length of hospital stay and if it is associated with differences in short-term progress.
Method
Patients from the EAHFE registry diagnosed with AHF who were admitted to the SSU (SSU group) were included and compared to those hospitalized in other departments (non-SSU group) from all hospitals (comparison A) and, separately, those from hospitals with an SSU (comparison B) and without an SSU (comparison C). For each comparison, patients in the SSU/non-SSU groups were matched by propensity score. The length of hospital stay (efficacy), 30-day mortality, and post-discharge adverse events at 30 days (safety) were compared.
Results
A total of 2,003 SSU patients and 12,193 non-SSU patients were identified. Of them, 674 pairs of patients were matched for comparison A, 634 for comparison B, and 588 for comparison C. The hospital stay was significantly shorter in the SSU group in all comparisons (A: median 4 days (IQR = 2–5) versus 8 (5–12) days, p < 0.001; B: 4 (2–5) versus 8 (5–12), p < 0.001; C: 4 (2–5) versus 8 (6–12), p < 0.001). Admission to the SSU was not associated with differences in mortality (A: HR = 1.027, 95%CI = 0.681–1.549; B: 0.976, 0.647–1.472; C: 0.818, 0.662–1.010) or post-discharge adverse events (A: HR = 1.002, 95%CI = 0.816–1.232; B: 0.983, 0.796–1.215; C: 1.135, 0.905–1.424).
Conclusion
The hospitalization of patients with AHF in the SSU is associated with shorter hospital stays but there were no differences in short-term progress.
Resumen
Objetivos
Analizar si la hospitalización en unidades de corta estancia (UCE) de pacientes diagnosticados en urgencias de insuficiencia cardíaca aguda (ICA) resulta efectiva en términos de estancia hospitalaria y si se asocia con diferencias en la evolución a corto plazo.
Método
Se incluyeron los pacientes del registro EAHFE diagnosticados de ICA que ingresaron en UCE (grupo UCE) y se compararon con los hospitalizados en otros servicios (grupo No-UCE) procedentes de todos los hospitales (comparación A) y, separadamente, de hospitales con UCE (comparación B) y sin UCE (comparación C). Para cada comparación, se emparejaron pacientes de los grupos UCE/No-UCE por puntuación de propensión, y se comparó la estancia hospitalaria (eficacia) y mortalidad a 30 días y evento adverso postalta a 30 días (seguridad).
Resultados
Se identificaron 2.003 pacientes UCE y 12.193 No-UCE. Se emparejaron 674 pares de pacientes para la comparación A, 634 para la comparación B y 588 para la comparación C. La estancia hospitalaria fue significativamente inferior en el grupo UCE en todas las comparaciones (A: mediana 4 días [RIC = 2-5] versus 8 [5-12] días, p < 0,001; B: 4 [2-5] versus 8 [5-12], p < 0,001; C: 4 [2-5] versus 8 [6-12], p < 0,001). El ingreso en UCE no se asoció a diferencias en mortalidad (A: HR = 1,027; IC95% = 0,681-1,549; B: 0,976; 0,647-1,472; C: 0,818; 0,662-1,010) ni en eventos adversos postalta (A: 1,002; 0,816-1,232; B: 0,983; 0,796-1,215; C: 1,135; 0,905-1,424).
Conclusión
La hospitalización de los pacientes con ICA en UCE se asocia con estancias más cortas sin diferencias en la evolución a corto plazo.
Objective
To describe the frequency, clinical characteristics and outcomes of patients with acute heart failure (AHF) transferred directly from emergency departments to home hospitalisation (HH) and to compare them with those hospitalised in internal medicine (IM) or short-stay units (SSU).
Method
We included patients with AHF transferred to HH by hospitals that considered this option during the Epidemiology of Acute Heart Failure in Spanish Emergency Departments (EAHFE) 4-5-6 Registries and compared them with patients admitted to IM or SSU in these centres. We compared the adjusted all-cause mortality at 1 year and adverse events 30 days after discharge.
Results
The study included 1473 patients (HH/IM/SSU:68/979/384). The HH rate was 4.7% (95% CI 3.8–6.0%). The patients in HH had few differences compared with those hospitalised in IM and SSUs. The HH mortality was 1.5%, and the HH median stay was 7.5 days (IQR, 4.5–12), similar to that of IM (median stay, 8 days; IQR, 5–13; p = .106) and longer than that of SSU (median stay, 4 days; IQR, 3–7; p < .001). The all-cause mortality at 1 year for HH did not differ from that of IM (HR, 0.91; 95% CI 0.73–1.14) or SSU (HR, 0.77; 95% CI 0.46–1.27); however, the emergency department readmission rate during the 30 days postdischarge was lower than that of IM (HR, 0.50; 95% CI 0.25–0.97) and SSU (HR, 0.37; 95% CI 0.19–0.74). There were no differences in the need for new hospitalisations or in the 30-day mortality rate.
Conclusions
Direct transfer from the emergency department to HH is infrequent despite being a safe option for a certain patient profile with AHF.
Resumen
Objetivo
Describir frecuencia, características clínicas y evolución de los pacientes con insuficiencia cardiaca aguda (ICA) ingresados directamente desde urgencias en hospitalización a domicilio (HaD) así como compararlos con los ingresados en medicina interna (MI) o unidad de corta estancia (UCE).
Método
Se incluyeron los pacientes con ICA ingresados en HaD por parte de los hospitales que contemplaban esta opción durante los Registros EAHFE 4-5-6 y se compararon con los casos que ingresaron en MI o UCE en estos centros. Se compararon la mortalidad por cualquier causa al año y los eventos adversos a los 30 días tras el alta de forma ajustada.
Resultados
Se incluyeron 1.473 pacientes (HaD/MI/UCE: 68/979/384). La frecuencia de HaD fue del 4,7% (IC95% = 3,8-6,0%). Los pacientes en HaD tuvieron escasas diferencias respecto a los ingresados en MI y UCE. Su mortalidad durante el ingreso fue del 1,5% y la duración de la estancia mediana fue de 7,5 días (RIC = 4,5-12), parecida a MI (mediana = 8; RIC = 5-13; p = 0,106) y superior a UCE (mediana = 4; RIC = 3-7; p < 0,001). La mortalidad por cualquier causa al año en HaD no difirió respecto a MI (HR = 0,91; IC95% = 0,73-1,14) o UCE (HR = 0,77; IC95% = 0,46-1,27), pero la reconsulta a urgencias durante los 30 días postalta fue menor respecto a MI (HR = 0,50; IC95% = 0,25-0,97) y a UCE (HR = 0,37; IC95% = 0,19-0,74). No hubo diferencias en la necesidad de nuevas hospitalizaciones o en la mortalidad a 30 días.
Conclusiones
El ingreso directo desde urgencias en HaD es poco frecuente a pesar de ser una opción segura en un determinado perfil de pacientes con ICA.
Aim:
The clinical value of single biomarkers at single time-points to predict outcomes in patients with acute heart failure (AHF) is limited. We performed a multimarker, multi-time-point analysis of biomarkers for the prediction of post-discharge clinical outcomes in high-risk AHF patients.
Methods and results:
A set of 48 circulating biomarkers were measured in the PROTECT trial which enrolled 2033 patients with AHF. Associations between baseline levels of biomarkers and outcomes (30-day all-cause mortality, 30-day death or rehospitalization for renal/cardiovascular causes and 180-day all-cause mortality) were evaluated. Prognostic accuracies of baseline, days 2 or 3, 7, and 14 biomarker measurements were estimated and compared utilizing a time-dependent area under the curve (AUC) analysis. Forty-four biomarkers were significantly associated with outcomes, but 42 had limited prognostic value (C-index < 0.70). However, multimarker models combining best-performing biomarkers from different clusters had a much stronger prognostic value. Combining blood urea nitrogen (BUN), chloride, interleukin (IL)-6, cTnI, sST-2 and VEGFR-1 into a clinical model yielded a 11% increase in C-index to 0.84 and 0.78 for 30-day and 180-day all-cause mortality, respectively, and cNRI of 0.86 95% CI [0.55-1.11] and 0.76 95% CI [0.57-0.87]. Prognostic gain was modest for the 30-day death/rehospitalization for cardiovascular or renal causes endpoint. Comparative time-dependent AUC analysis indicated that late measurements provided superior accuracy for the prediction of all-cause mortality over 180 days, with few exceptions including BUN and galectin-3. However, the predictive value of most biomarkers showed a diminishing pattern over time irrespective of moment of measurement.
Conclusions:
Multimarker models significantly improve risk prediction. Subsequent measurements, beyond admission, are needed for majority of biomarkers to maximize prognostic value over time, particularly in the long term.
En:
Acute heart failure (AHF) requires considerable use of resources, is an economic burden, and is associated with high complication and mortality rates in emergency departments, on hospital wards, or outpatient care settings. Diagnosis, treatment, and continuity of care are variable at present, leading 3 medical associations (for cardiology, internal medicine, and emergency medicine) to undertake discussions and arrive at a consensus on clinical practice guidelines to support those who manage AHF and encourage standardized decision making. These guidelines, based on a review of the literature and clinical experience with AHF, focus on critical points in the care pathway. Regarding emergency care, the expert participants considered the initial evaluation of patients with signs and symptoms that suggest AHF, the initial diagnosis, first decisions about therapy, monitoring, assessment of prognosis, and referral criteria. For care of the hospitalized patient, the group developed a protocol for essential treatment. Objectives for the management and treatment of AHF on discharge were also covered through the creation or improvement of multidisciplinary care systems to provide continuity of care.
Importance:
In PIONEER-HF, among stabilized patients with acute decompensated heart failure (ADHF), the in-hospital initiation of sacubitril/valsartan was well tolerated and led to improved outcomes compared with enalapril. However, there are limited data comparing the strategies of in-hospital vs postdischarge initiation of sacubitril/valsartan.
Objective:
To describe changes in N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels in patients recently hospitalized for ADHF and switching from taking enalapril to taking sacubitril/valsartan after discharge and compare clinical outcomes for patients randomized to receive in-hospital initiation of sacubitril/valsartan vs in-hospital initiation of enalapril who later switched to taking sacubitril/valsartan during an open-label extension phase.
Interventions:
Sacubitril/valsartan titrated to 97/103 mg twice daily.
Design, setting, and participants:
The PIONEER-HF trial was a multicenter, randomized, double-blind, active-controlled trial conducted at 129 US sites between May 2016 and May 2018 that compared the in-hospital initiation of sacubitril/valsartan vs enalapril (titrated to target dose, 10 mg twice daily) for 8 weeks among patients admitted for ADHF with reduced ejection fraction and hemodynamic stability. All patients were to continue in a 4-week, open-label study of sacubitril/valsartan; of 881 patients enrolled in PIONEER-HF, 832 (94%) continued in the open-label study.
Main outcomes and measures:
Changes in NT-proBNP levels from week 8 to 12 as well as the exploratory composite of heart failure rehospitalization or cardiovascular death from randomization through week 12.
Results:
Of 881 participants, 226 (27.7%) were women, 487 (58.5%) were white, 297 (35.7%) were black, 15 (1.8%) were Asian, and 73 (8.8%) were of Hispanic ethnicity; the mean (SD) age was 61 (14) years. For patients who continued to take sacubitril/valsartan, NT-proBNP levels declined -17.2% (95% CI, -3.2 to -29.1) from week 8 to 12. The NT-proBNP levels declined to a greater extent for those switching from taking enalapril to sacubitril/valsartan after the week 8 visit (-37.4%; 95% CI, -28.1 to -45.6; P < .001; comparing changes in 2 groups). Over the entire 12 weeks of follow-up, patients that began taking sacubitril/valsartan in the hospital had a lower hazard for the composite outcome compared with patients that initiated enalapril in the hospital and then had a delayed initiation of sacubitril/valsartan 8 weeks later (hazard ratio, 0.69; 95% CI 0.49-0.97).
Conclusions and relevance:
Switching patients' treatment from enalapril to sacubitril/valsartan at 8 weeks after randomization led to a further 37% reduction in NT-proBNP levels in patients with heart failure with reduced ejection fraction and a recent hospitalization for ADHF.
Trial registration:
ClinicalTrials.gov identifier: NCT02554890.
Acute heart failure is one of the main diagnostic and therapeutic challenges in clinical practice due to a non‐specific clinical manifestation and the urgent need for timely and tailored management at the same time. In this position statement, the Heart Failure Association aims to systematize the use of various imaging methods in accordance with the timeline of acute heart failure care proposed in the recent guidelines of the European Society of Cardiology. During the first hours of admission the point‐of‐care focused cardiac and lung ultrasound examination is an invaluable tool for rapid differential diagnosis of acute dyspnoea, which is highly feasible and relatively easy to learn. Several portable and stationary imaging modalities are being increasingly used for the evaluation of cardiac structure and function, haemodynamic and volume status, precipitating myocardial ischaemia or valvular abnormalities, and systemic and pulmonary congestion. This paper emphasizes the central role of the full echocardiographic examination in the identification of heart failure aetiology, severity of cardiac dysfunction, indications for specific heart failure therapy, and risk stratification. Correct evaluation of cardiac filling pressures and accurate prognostication may help to prevent unscheduled short‐term readmission. Alternative advanced imaging modalities should be considered to assist patient management in the pre‐ and post‐discharge phase, including cardiac magnetic resonance, computed tomography, nuclear studies, and coronary angiography. The Heart Failure Association addresses this paper to the wide spectrum of acute care and heart failure specialists, highlighting the value of all available imaging techniques at specific stages and in common clinical scenarios of acute heart failure.
The ESC has published a series of guidelines on heart failure (HF) over the last 25 years, most recently in 2016. Given the amount of new information that has become available since then, the HFA of the ESC recognized the need to review and summarise recent developments in a consensus document. Here we report from the HFA workshop that was held in January 2019 in Frankfurt. This expert consensus report is neither a guideline update nor a position statement, but rather a summary and consensus view in the form of consensus recommendations. The report describes how these guidance statements are supported by evidence, it makes some practical comments, and it highlights new research areas and how progress there might change the clinical management of HF. We have avoided re‐interpretation of information already considered in the 2016 ESC/HFA guidelines.
Specific new recommendations have been made based on the evidence from major trials published since 2016, including SGLT2 inhibitors in type 2 diabetes mellitus; MitraClip for functional mitral regurgitation; atrial fibrillation ablation in HF; tafamidis in cardiac transthyretin amyloidosis; rivaroxaban in HF; ICD's in non‐ischaemic HF; and telemedicine for HF. In addition, new trial evidence from smaller trials and updated meta‐analyses have given us the chance to provide refined recommendations in selected other areas.
Further, new trial evidence is due in many of these areas and others over the next two years, in time for the planned 2021 ESC guidelines on the diagnosis and treatment of acute and chronic heart failure.
Patients with worsening heart failure with reduced ejection fraction (HFrEF) spend a large proportion of time in the hospital and other health care facilities. The benefits of guideline-directed medical therapy (GDMT) in the outpatient setting have been shown in large randomized controlled trials. However, the decision to initiate, continue, switch, or withdraw HFrEF medications in the inpatient setting is often based on multiple factors and subject to significant variability across providers. Based on available data, in well-selected, treatment-naïve patients who are hemodynamically stable and clinically euvolemic after stabilization during hospitalization for HF, elements of GDMT can be safely initiated. Inpatient continuation of GDMT for HFrEF appears safe and well-tolerated in most hemodynamically stable patients. Hospitalization is also a potential time for switching from an angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker to sacubitril/valsartan therapy in eligible patients, and is the subject of ongoing study. Therapy withdrawal or need for dose reduction is rarely required, but if needed identifies a particularly at-risk group of patients with progressive HF. If recurrent intolerance to neurohormonal blockers is observed, these patients should be evaluated for advanced HF therapies. There is an enduring need for using the teachable moment of HFrEF hospitalization for optimal initiation, continuation, and switching of GDMT to improve post-discharge patient outcomes and the quality of chronic HFrEF care.
Aims:
To identify differences in clinical epidemiology, in-hospital management and 1-year outcomes among patients hospitalized for acute heart failure (AHF) and enrolled in the European Society of Cardiology Heart Failure Long-Term (ESC-HF-LT) Registry, stratified by clinical profile at admission.
Methods and results:
The ESC-HF-LT Registry is a prospective, observational study collecting hospitalization and 1-year follow-up data from 6629 AHF patients. Among AHF patients enrolled in the registry, 13.2% presented with pulmonary oedema (PO), 2.9% with cardiogenic shock (CS), 61.1% with decompensated heart failure (DHF), 4.8% with hypertensive heart failure (HT-HF), 3.5% with right heart failure (RHF) and 14.4% with AHF and associated acute coronary syndromes (ACS-HF). The 1-year mortality rate was 28.1% in PO, 54.0% in CS, 27.2% in DHF, 12.8% in HT-HF, 34.0% in RHF and 20.6% in ACS-HF patients. When patients were classified by systolic blood pressure (SBP) at initial presentation, 1-year mortality was 34.8% in patients with SBP <85 mmHg, 29.0% in those with SBP 85-110 mmHg, 21.2% in patients with SBP 110-140 mmHg and 17.4% in those with SBP >140 mmHg. These differences tended to diminish in the months post-discharge, and 1-year mortality for the patients who survived at least 6 months post-discharge did not vary significantly by either clinical profile or SBP classification.
Conclusion:
Rates of adverse outcomes in AHF remain high, and substantial differences have been found when patients were stratified by clinical profile or SBP. However, patients who survived at least 6 months post-discharge represent a more homogeneous group and their 1-year outcome is less influenced by clinical profile or SBP at admission.
Acute heart failure (AHF) is a multi-organ dysfunction syndrome. In addition to known cardiac dysfunction, non-cardiac comorbidity, frailty and disability are independent risk factors of mortality, morbidity, cognitive and functional decline, and risk of institutionalization. Frailty, a treatable and potential reversible syndrome very common in older patients with AHF, increases the risk of disability and other adverse health outcomes. This position paper highlights the need to identify frailty in order to improve prognosis, the risk-benefits of invasive diagnostic and therapeutic procedures, and the definition of older-person-centered and integrated care plans.
ACC/AHA
: American College of Cardiology/American Heart Association
ACCF/AHA
: American College of Cardiology Foundation/American Heart Association
ACE
: angiotensin-converting enzyme
ACEI
: angiotensin-converting enzyme inhibitor
ACS
: acute coronary syndrome
AF
: atrial fibrillation
Heart failure is a global public health challenge frequently presenting to the emergency department. After initial stabilization and management, one of the most important decisions is to determine which patients can be safely discharged and which require hospitalization. This is a complex decision that depends on numerous subjective factors, including both the severity of the patient's underlying condition and an estimate of the acuity of the presentation. An emergency department observation period may help select the correct option. Ideally, during an observation period, risk stratification should be carried out using parameters specifically designed for use in the emergency department. Unfortunately, there is little objective literature to guide this disposition decision. An objective and reliable definition of low-risk characteristics to identify early discharge candidates is needed. Benchmarking outcomes in patients discharged from the emergency department without hospitalization could aid this process. Biomarker determinations, although undoubtedly useful in establishing diagnosis and predicting longer-term prognosis, require prospective validation for emergency department disposition guidance. The challenge of identifying emergency department acute heart failure discharge candidates will only be overcome by future multidisciplinary research defining the current knowledge gaps and identifying potential solutions.
Acute heart failure constitutes a heterogeneous clinical syndrome, whose pathophysiology is complex and not completely understood. Given the diversity of clinical presentations, several different pathophysiological mechanisms along with factors triggering circulatory decompensation are involved. This article discusses the available evidence on the pathophysiological phenomena attributed or/and associated with episodes of acute heart failure and describes different clinical profiles, which, from a clinical perspective, constitute a key element for therapeutic decision-making.
Copyright © 2015 Sociedad Española de Cardiología. Published by Elsevier España, S.L.U. All rights reserved.
MEESSI-AHF: una escala derivada y validada en servicios de urgencias españoles para estratificar el riesgo de los pacientes que consultan por insuficiencia cardiaca aguda
- Miró Andreu
Recommendations of the Geriatric Cardiology Section of the Spanish Society of Cardiology for the assessment of frailty in elderly patients with heart disease
- Díez-Villanueva
editor hospital to home (H2H): Excellence in transitions. The changing landscape of cardiovascular care
- R G Brindis
Brindis RG. editor hospital to home (H2H): Excellence in transitions. The changing landscape of cardiovascular care. En: The
21st Annual Conference of the Michigan Chapter ACC. Grand
Rapids, MI: Muichigan Chapter ACC; 2009.
Clinical phenotypes and outcome of patients hospitalized for acute heart failure: The ESC Heart Failure Long-Term Registry
- O Chioncel
- A Mebazaa
- V P Harjola
- A J Coats
- M F Piepoli
- M G Crespo-Leiro
Chioncel O, Mebazaa A, Harjola VP, Coats AJ, Piepoli MF,
Crespo-Leiro MG, et al. Clinical phenotypes and outcome of
patients hospitalized for acute heart failure: The ESC Heart
Failure Long-Term Registry. Eur J Heart Fail. 2017;19:1242---54,
http://dx.doi.org/10.1002/ejhf.890.
MEESSI-AHF: una escala derivada y validada en servicios de urgencias españoles para estratificar el riesgo de los pacientes que consultan por insuficiencia cardiaca aguda
- Miró Andreu
- Ò Rosselló
- X Bueno
- Martín Sánchez
- Gil Espinosa
- Herrero Puente
Miró Andreu Ò, Rosselló X, Bueno H, Martín Sánchez FJ, Gil Espinosa V, Herrero Puente P, et al. MEESSI-AHF: una escala derivada
y validada en servicios de urgencias españoles para estratificar el
riesgo de los pacientes que consultan por insuficiencia cardiaca
aguda. Rev Esp Cardiol. 2016;69 Supl 1:484.
Recommendations of the Geriatric Cardiology Section of the Spanish Society of Cardiology for the assessment of frailty in elderly patients with heart disease
- P Díez-Villanueva
- A Arizá-Solé
- M T Vidán
- C Bonanad
- F Formiga
- J Sanchis
Díez-Villanueva P, Arizá-Solé A, Vidán MT, Bonanad C, Formiga F, Sanchis J, et al. Recommendations of the Geriatric
Cardiology Section of the Spanish Society of Cardiology
for the assessment of frailty in elderly patients with
heart disease. Rev Esp Cardiol (Engl Ed). 2019;72:63---71,
http://dx.doi.org/10.1016/j.rec.2018.06.035.
Practical approach on frail older patients attended for acute heart failure
- F J Martín-Sánchez
- M Christ
- Ò Miró
- W F Peacock
- J J Mcmurray
- H Bueno
Martín-Sánchez FJ, Christ M, Miró Ò, Peacock WF, McMurray
JJ, Bueno H, et al. Practical approach on frail older patients
attended for acute heart failure. Int J Cardiol. 2016;222:62---71,
http://dx.doi.org/10.1016/j.ijcard.2016.07.151.
European Society of Cardiology -Acute Cardiovascular Care Association position paper on safe discharge of acute heart failure patients from the emergency department
- Ò Miró
- F W Peacock
- J J Mcmurray
- H Bueno
- M Christ
- A S Maisel
Miró Ò, Peacock FW, McMurray JJ, Bueno H, Christ M, Maisel
AS, et al. European Society of Cardiology -Acute Cardiovascular Care Association position paper on safe discharge
of acute heart failure patients from the emergency department. Eur Heart J Acute Cardiovasc Care. 2017;6:311---20,
http://dx.doi.org/10.1177/2048872616633853.
Decálogo de la transición del paciente hospitalizado por IC: Sociedad Española de Cardiología (SEC)
Decálogo de la transición del paciente hospitalizado por IC:
Sociedad Española de Cardiología (SEC); 2018. Disponible en:
https://secardiologia.es/images/secciones/insuficiencia/ent
decalogo transicion.pdf.
Clinical practice update on heart failure 2019: Pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of The Heart Failure Association of the European Society of Cardiology
- P M Seferovic
- P Ponikowski
- S D Anker
- J Bauersachs
- O Chioncel
- Jgf Cleland
Seferovic PM, Ponikowski P, Anker SD, Bauersachs J, Chioncel O,
Cleland JGF, et al. Clinical practice update on heart failure 2019:
Pharmacotherapy, procedures, devices and patient management.
An expert consensus meeting report of The Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail.
2019;21:1169---86, http://dx.doi.org/10.1002/ejhf.1531.
Optimizing clinical use of biomarkers in high-risk acute heart failure patients
- B G Demissei
- M A Valente
- J G Cleland
- O' Connor
- C M Metra
- M Ponikowski
Demissei BG, Valente MA, Cleland JG, O'Connor CM, Metra
M, Ponikowski P, et al. Optimizing clinical use of biomarkers
in high-risk acute heart failure patients. Eur J Heart Fail.
2016;18:269---80, http://dx.doi.org/10.1002/ejhf.443.